# Verve Therapeutics Inc. (VERV)

Source: https://www.quantisnow.com/company/VERV
Generated: 2026-10-29T20:41:08.789Z

- Ticker: VERV
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: vervetx.com

## About

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.

## Latest VERV news and filings

- 2025-08-04 12:00 UTC [SEC Form 15-12G filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-verve-therapeutics-inc-6144003)
- 2025-07-29 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-verve-therapeutics-inc-6135118)
- 2025-07-28 21:21 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-verve-therapeutics-inc-6134835)
- 2025-07-28 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Maclean Michael F](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-maclean-michael-f-6134813)
- 2025-07-28 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Yeshwant Krishna](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-yeshwant-krishna-6134812)
- 2025-07-28 21:15 UTC [SEC Form 4] [Chief Administrative Officer Nickerson Joan closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-administrative-officer-nickerson-joan-closing-all-direct-ownership-in-6134809)
- 2025-07-28 21:15 UTC [SEC Form 4] [Chief Executive Officer Kathiresan Sekar closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-kathiresan-sekar-closing-all-direct-ownership-in-6134808)
- 2025-07-28 21:15 UTC [SEC Form 4] [Chief Scientific Officer Lister Troy closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lister-troy-closing-all-direct-ownership-in-6134807)
- 2025-07-28 21:15 UTC [SEC Form 4] [Chief Financial Officer Dorval Allison closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-dorval-allison-closing-all-direct-ownership-in-6134806)
- 2025-07-28 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Adelman Burt A](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-adelman-burt-a-6134805)
- 2025-07-28 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Morrison Jodie Pope](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-morrison-jodie-pope-6134804)
- 2025-07-28 21:15 UTC [SEC Form 4] [Officer Ashe Andrew D. closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-ashe-andrew-d-closing-all-direct-ownership-in-the-6134803)
- 2025-07-28 21:15 UTC [SEC Form 4] [Chief Technical Ops. Off. Politi Jason closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-technical-ops-off-politi-jason-closing-all-direct-ownership-6134802)
- 2025-07-28 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Coats Lonnel](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-coats-lonnel-6134801)
- 2025-07-28 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Cumbo Alexander](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cumbo-alexander-6134799)
- 2025-07-28 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Mikhail Sheila](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mikhail-sheila-6134798)
- 2025-07-28 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Tatsis Ourania](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-tatsis-ourania-6134797)
- 2025-07-25 21:12 UTC [SEC Form POS AM filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-verve-therapeutics-inc-6133355)
- 2025-07-25 20:16 UTC [SEC Form 8-K] [SEC Form 8-K filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-verve-therapeutics-inc-6133091)
- 2025-07-25 15:46 UTC [SEC Form POSASR filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-verve-therapeutics-inc-6132797)
- 2025-07-25 15:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verve-therapeutics-inc-6132795)
- 2025-07-25 15:38 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verve-therapeutics-inc-6132793)
- 2025-07-25 15:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verve-therapeutics-inc-6132791)
- 2025-07-25 15:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verve-therapeutics-inc-6132790)
- 2025-07-25 15:30 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verve-therapeutics-inc-6132789)
- 2025-07-25 12:49 UTC [Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk](https://www.quantisnow.com/insight/lilly-completes-acquisition-of-verve-therapeutics-to-advance-one-time-treatments-6132632)
- 2025-07-25 12:30 UTC [SEC Form 25-NSE filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-verve-therapeutics-inc-6132616)
- 2025-07-24 12:50 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-verve-therapeutics-inc-6131033)
- 2025-07-24 12:12 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-verve-therapeutics-inc-6130926)
- 2025-07-24 12:00 UTC [Lilly and Verve announce expiration of Verve tender offer](https://www.quantisnow.com/insight/lilly-and-verve-announce-expiration-of-verve-tender-offer-6130828)
- 2025-07-22 21:17 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-verve-therapeutics-inc-6128619)
- 2025-07-22 21:16 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-verve-therapeutics-inc-6128615)
- 2025-07-15 10:16 UTC [SEC Form 8-K] [SEC Form 8-K filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-verve-therapeutics-inc-6119790)
- 2025-07-15 10:14 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-verve-therapeutics-inc-6119784)
- 2025-07-15 10:04 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-verve-therapeutics-inc-6119762)
- 2025-06-25 11:00 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-verve-therapeutics-inc-6098211)
- 2025-06-25 10:10 UTC [SEC Schedule TOT] [SEC Form SC TO-T filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-t-filed-by-verve-therapeutics-inc-6098154)
- 2025-06-17 20:21 UTC [SEC Form SC14D9C filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-verve-therapeutics-inc-6090055)
- 2025-06-17 20:04 UTC [SEC Form SC TO-C filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-c-filed-by-verve-therapeutics-inc-6089815)
- 2025-06-17 11:18 UTC [SEC Form 8-K] [SEC Form 8-K filed by Verve Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-verve-therapeutics-inc-6089142)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VERV
- RSS and alerts for VERV: https://www.quantisnow.com/docs/rss-feeds.md